Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × HER2-negative Breast Cancer × Epirubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 8 Stomach Neoplasms 2 Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Oesophagogastric Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 HER2-negative Breast Cancer 1 Carcinoma, Hepatocellular 1 Breast Diseases 1

Interventions

Paclitaxel 1 Epirubicin 1 Docetaxel 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04576143 2021-08-12

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡